Ventricular tachycardia Circulatory System Cardiac arrhythmia
Conditions
Interventions
Randomisation between:
1. Implantable defibrillator
2. Implantable defibrillator plus catheter ablation of ventricular tachycardia
Sponsors
Beth Israel - Deaconess Hospital (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Men and women who were at least 18 years old were eligible for the study if they had a history of an MI as documented by an electrocardiogram or cardiac imaging and had a planned or recent (within six months) implantation of an ICD for either: 1. Ventricular Fibrillation (VF) arrest 2. Hemodynamically-unstable Ventricular Tachycardia (VT) 3. Syncope and inducible VT during invasive electrophysiologic testing (for this group, syncope is assumed to be the qualifying spontaneous arrhythmic event) 4. Patients who had received an ICD for primary prophylaxis and then experienced a single appropriate ICD therapy
Exclusion criteria
Exclusion criteria: 1. Treated with a Class I/III antiarrhythmic drug 2. The substrate for the ventricular arrhythmia was thought not to be due to the myocardial infarction 3. Active ongoing cardiac ischemia was felt to be the cause of the ventricular arrhythmia; 4. Incessant or multiple VT episodes necessitating some form of treatment ? drugs or ablation 5. Unable to give informed consent 6. If the patient had experienced a stroke within 30 days 7. Contraindication to anticoagulation 8. Any medical/non-medical condition likely to prevent completion of the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Defibrillator events (shocks and anti-tachycardia therapy) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mortality 2. ICD shocks 3. Left ventricular ejection fraction 4. Heart failure status | — |
Countries
Czech Republic, United States of America
Outcome results
None listed